Dermatology

Calcipotriol with betamethasone dipropionate, ointment

Brand: Daivobet®

PBAC's latest decision on Calcipotriol with betamethasone dipropionate, ointment: Recommended with restriction (2009). Considered for chronic stable plaque type psoriasis vulgaris in patients not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy.

PBAC outcome

Recommended with restriction

Restricted Benefit

ICER (AUD/QALY)

Cost-min

cost-minimisation analysis

Submissions

first 2009

Submissions

2009 → 2009

Eligible population

chronic stable plaque type psoriasis vulgaris in patients not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy

Therapy area: Dermatology
Line of therapy: Later-line
Evidence base: RCT
Primary endpoint: PASI (Psoriasis Area and Severity Index)
Key trials: Trial 9802, Trial 9904, Trial 0003, Trial 9905, Saraceno (2007), Ruzicka (1998)
Comparator: calcipotriol and betamethasone dipropionate individual components given concomitantly
Economic model: Cost minimisation
ICER note: Cost minimisation analysis performed; no ICER calculated

Open on full dashboard →